American Association of Pharmaceutical Scientists
Trade associationSupport
Supac guidance clarity
Recommendations on Scale-Up and Postapproval Changes Guidances for Industry; Request for Comments
FDA-2026-N-0809-0001RFI
Comments
52
Last activity Jul 13, 2026
Deadline
Closed on Jul 14, 2026
Closed Jul 14, 2026
Net supportiSupport minus oppose · campaigns included
+90%
+90% excluding campaigns
Document
Details
The document's own metadata, straight from the source system.
- Title
- Recommendations on Scale-Up and Postapproval Changes Guidances for Industry; Request for Comments
- Posted
- Mar 3, 2026
- Comment period
- Mar 3, 2026 – Jul 14, 2026
- FR Doc
- 2026-04196
- Topics
Analysis
Overview
What the public is saying — stance, who's commenting, and the issues they raise.
Include campaigns
Stance breakdown
+90%
Net support
Support48Oppose1Other3
Aggregates include form-letter campaigns. Excluding them, net support is +90% across organic comments.
Who commented
Breakdown by commenter type.
Business
12
Government
2
Individual
18
Trade association
4
Advocacy
12
Other
4
Comments over time
Weekly arrivals, stacked by stance.
Posted Mar 3, 2026Deadline Jul 14, 2026
Mar 9Mar 30Apr 20May 25Jun 8Jun 29Jul 13
Support48Oppose1Other1
Support × commenter type
How each type splits across stance.
Support
Oppose
Other
Individual
89%
6%
6%
Business
100%
0%
0%
Advocacy
100%
0%
0%
Trade association
100%
0%
0%
Other
100%
0%
0%
Government
0%
0%
100%
Issues raised
The docket's canonical issues. Select one to browse its comments.
Position map
Who stands where on each issue?
Every non-silent position is backed by an excerpt from the comment.
Issues shown
Choose up to five.
| Organization | Supac guidance clarity | Additional change types | Guidance consolidation |
|---|---|---|---|
American Association of Pharmaceutical Scientists Trade associationSupport The American Association of Pharmaceutical Scientists (AAPS) supports the proposed guidance but requests specific update | · | · | |
Lonza BusinessSupport Lonza, a Contract Development and Manufacturing Organization (CDMO), supports the FDA's initiative to update the SUPAC g | · | · |
Lonza
BusinessSupport
Supac guidance clarity
13 organization-typed comments could not be identified.
Comments
Explorer
Every mirrored comment — filter by stance, campaign, or issue.